Abeona Therapeutics’ (ABEO) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Abeona Therapeutics (NASDAQ:ABEO) in a research report report published on Monday,Benzinga reports. The brokerage currently has a $20.00 price objective on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Abeona Therapeutics’ Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at $0.04 EPS, FY2025 earnings at $1.49 EPS, Q1 2026 earnings at $0.04 EPS, Q2 2026 earnings at $0.07 EPS, Q3 2026 earnings at $0.12 EPS, Q4 2026 earnings at $0.19 EPS and FY2026 earnings at $0.42 EPS.

A number of other equities research analysts have also recently commented on the company. Oppenheimer lifted their price objective on Abeona Therapeutics from $19.00 to $20.00 and gave the stock an “outperform” rating in a research note on Friday, August 15th. Stifel Nicolaus reduced their price target on shares of Abeona Therapeutics from $21.00 to $20.00 and set a “buy” rating on the stock in a research report on Friday, May 16th. Wall Street Zen lowered Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 15th. Finally, Alliance Global Partners reiterated a “buy” rating on shares of Abeona Therapeutics in a report on Thursday, May 15th. Five research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Abeona Therapeutics has a consensus rating of “Buy” and an average target price of $19.50.

Abeona Therapeutics Trading Up 2.3%

ABEO stock opened at $7.00 on Monday. Abeona Therapeutics has a fifty-two week low of $3.93 and a fifty-two week high of $7.54. The stock has a market capitalization of $358.96 million, a price-to-earnings ratio of 10.00 and a beta of 1.55. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.73 and a quick ratio of 4.90. The business has a fifty day moving average price of $6.26 and a 200 day moving average price of $5.77.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported $1.71 earnings per share for the quarter, beating the consensus estimate of ($0.39) by $2.10. The company had revenue of $0.40 million during the quarter, compared to analyst estimates of $21.71 million. Analysts expect that Abeona Therapeutics will post -1.16 EPS for the current fiscal year.

Insider Transactions at Abeona Therapeutics

In other Abeona Therapeutics news, Director Mark Alvino sold 13,093 shares of Abeona Therapeutics stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $5.86, for a total transaction of $76,724.98. Following the transaction, the director directly owned 77,252 shares of the company’s stock, valued at approximately $452,696.72. The trade was a 14.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Faith L. Charles sold 10,738 shares of Abeona Therapeutics stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $5.86, for a total value of $62,924.68. Following the completion of the sale, the director owned 139,094 shares of the company’s stock, valued at approximately $815,090.84. The trade was a 7.17% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 231,626 shares of company stock worth $1,430,587. 6.90% of the stock is owned by insiders.

Institutional Trading of Abeona Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Adage Capital Partners GP L.L.C. grew its holdings in Abeona Therapeutics by 20.1% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,902,360 shares of the biopharmaceutical company’s stock valued at $21,736,000 after purchasing an additional 652,366 shares during the period. Oxford Asset Management LLP purchased a new stake in Abeona Therapeutics in the fourth quarter worth $118,000. Northern Trust Corp lifted its holdings in shares of Abeona Therapeutics by 6.6% during the fourth quarter. Northern Trust Corp now owns 184,929 shares of the biopharmaceutical company’s stock valued at $1,030,000 after purchasing an additional 11,478 shares during the last quarter. Schonfeld Strategic Advisors LLC purchased a new position in Abeona Therapeutics in the 4th quarter worth approximately $341,000. Finally, Jane Street Group LLC increased its holdings in Abeona Therapeutics by 894.8% during the fourth quarter. Jane Street Group LLC now owns 131,478 shares of the biopharmaceutical company’s stock valued at $732,000 after buying an additional 118,262 shares during the last quarter. 80.56% of the stock is owned by institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.